MIS-C displays clinical, proteomic heterogeneity, ‘outsized’ CXCL9 levels

mis c displays clinical proteomic heterogeneity outsized cxcl9 levels

Sumary of MIS-C displays clinical, proteomic heterogeneity, ‘outsized’ CXCL9 levels:

  • November 15, 2021 2 min read Source/Disclosures Published by: Source: Behrens E.
  • Source: Adobe Stock “Multisystem inflammatory syndrome in children, or MIS-C, is a post-infectious complication of pediatric SARS-CoV-2, typically occurring 3 to 4 weeks after asymptomatic exposure,” Edward Behrens, MD, of the Children’s Hospital of Philadelphia, told attendees at the virtual meeting.
  • ” “It was originally recognized as a Kawasaki’s disease-like syndrome, with many patients also having coronary artery aneurisms or dilation,” he added.
  • Using the Olink Explore 1536/384 protein biomarker platform, Behrens and colleagues interrogated the plasma proteome of all 88 patients.
  • The researchers created a principal component analysis (PCA) that mapped all proteins and all patients in order to better understand how the overall proteome of patients with MIS-C changes over time.
  • When they analyzed CXCL9 as the key protein associated with IFNg response, they found that all patients with COVID-19 demonstrated a positive CXCL9 response to increasing IFNg.
  • MIS-C patients also expressed less TRIM21 protein compared to healthy patients, consistent with a derepression of IFNg signaling.
  • According to Behrens, unsupervised hierarchical clustering revealed two distinct groups of patients with MIS-C demonstrating increases in multiple Macrophage Activation Syndrome (MAS) markers.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.